Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion

Annals of the Rheumatic Diseases

Volumn 61, Issue 10, 2002, Pages 883-888

  Leandro, M J ^a   Edwards, Jo C W ^a   Cambridge, G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; C REACTIVE PROTEIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; GOLD; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PARACETAMOL; PENICILLAMINE; PREDNISOLONE; RITUXIMAB; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BODY SURFACE; CELL POPULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE ACTIVITY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG SAFETY; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; FUNCTIONAL ASSESSMENT; HUMAN; LYMPHOCYTOPENIA; MALE; NAUSEA; PHLEBITIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; TACHYCARDIA; THROMBOCYTE COUNT; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PREDNISOLONE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0036785351     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.61.10.883     Document Type: Article

References (22)

1. Janossy G, Duke O, Poulter LW, Panayi G, Bofill M, Goldstein G. Rheumatoid arthritis: a disease of T lymphocyte-macrophage immunoregulation. Lancet 1981;ii:839-42.
2. Stastny P. Association of the B cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 1978;298:869-72.
3. Simon AK, Seipelt E, Sieper J. Divergent T-cell cytokine patterns in inflammatory arthritis. Proc Natl Acad Sci USA. 1994;91:8562-6.
4. Edwards JCW, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001;40:205-11.
5. Edwards JCW, Cambridge G, Abrahams VM. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology 1999;97:1868-96.
6. Feldmann M. Cell cooperation in the antibody response. In: Roitt IM, Brostoff J, Male D, eds. Immunology. London: Mosby, 1998:139-55.
7. Maini RN, Elliott M, Brennan FM, Williams RO, Feldmann M. TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesis. APMIS 1997;105:257-63
8. van de Winkel JG, Capel PJA. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today 1993;14:215-21.
9. Mannik M, Nardella FA. IgG rheumatoid factors and self-association of these antibodies. Clin Rheum Dis 1985;11:551-72.
10. Nardella FA, Dayer JM, Roelke M, Krane SM, Mannik M. Self-associating IgG rheumatoid factors stimulate monocytes to release prostaglandins and mononuclear cell factor that stimulates collagenase and prostaglandin production by synovial cells. Rheumatol Int 1983;3:183-6.
11. Abrahams VM, Cambridge G, Edwards JCW. Induction of tumour necrosis factor alpha production by human monocytes: a key role for FcγRIIIa in rheumatoid arthritis. Arthritis Rheum 2000;43:608-16.
12. Bhatia A, Blades S, Cambridge G, Edwards JCW. Differential distribution of FcγRIIIa in normal human tissues and co-localization with DAF and fibrillin-1: implications for immunological microenvironments. Immunology 1998;94:56-63.
13. Kraan MC, Versendaal H, Jonker M, Bresnihan B, Post WJ, 't-Hart BA, Breedveld FC, et al. Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum 1998;41:1481-8.
14. Roosnek E, Lanzavecchia A. Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J Exp Med 1991;173:487-9.
15. Fearon DT, Carter RH. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu Rev Immunol 1995;13:127-49.
16. Gopal AK, Press OW. Clinical applications of anti-CD20 antibodies. J Lab Clin Med 1999;134:445-50.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
18. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
19. Prevoo MLL, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLC. Modified Disease Activity Scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
20. Maloney DG, Grillo-Lopez AJ, Bodkin DJ. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997;15:3266-74.
21. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimaeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
22. Czuczman MS. CHOP plus rituximab chemoimmunotherapy of indolent B cell lymphoma. Semin Oncol 1999;26(suppl 4):88-96.